Skip to main content

Advertisement

  • Correction
  • Open Access

Corrections to: Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature

  • 1, 2,
  • 3,
  • 4,
  • 3,
  • 3,
  • 3,
  • 5,
  • 3,
  • 6,
  • 6,
  • 1 and
  • 3Email author
Contributed equally
Journal for ImmunoTherapy of Cancer20197:158

https://doi.org/10.1186/s40425-019-0639-4

  • Received: 14 June 2019
  • Accepted: 14 June 2019
  • Published:

The original article was published in Journal for ImmunoTherapy of Cancer 2019 7:106

Correction to: J Immunother Cancer (2019) 7:106

https://doi.org/10.1186/s40425-019-0585-1

Following publication of the original article [1], the authors reported an error in the Acknowledgments section. It should be read: ‘We are grateful to Mohsin Shah from the Department of Emergency Medicine at The University of Texas MD Anderson Cancer Center for assisting in study selection, and to Gregory F. Pratt from the Research Medical Library and Erica Goodoff, from the Department of Scientific Publications at The University of Texas MD Anderson Cancer Center for their valuable contributions.

Notes

Declarations

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
(2)
Department of Rheumatology and Rehabilitation, Faculty of Medicine, Assiut University Hospitals, Assiut, Egypt
(3)
Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
(4)
Section of Nephrology, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
(5)
Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
(6)
Houston Methodist Hospital, Houston, TX, USA

Reference

  1. Abdel-Wahab N, et al. Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature. J Immunother Cancer. 2019;7:106. https://doi.org/10.1186/s40425-019-0585-1.View ArticlePubMedPubMed CentralGoogle Scholar

Copyright

© The Author(s). 2019

Advertisement